Time course of early response to chemotherapy in non-small cell lung cancer patients with18F-FDG PET/CT

Journal of Nuclear Medicine

Volumn 48, Issue 5, 2007, Pages 744-751

  Nahmias, Claude ^a,c   Hanna, Wahid T ^a   Wahl, Lindi M ^b   Long, Misty J ^a   Hubner, Karl F ^a   Townsend, David W ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

18F FDG; Non small cell lung cancer; PET; Treatment monitoring

Indexed keywords

CARBOPLATIN; DOCETAXEL; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GEMCITABINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TAXOID;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METABOLISM; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; METABOLIC PARAMETERS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIOACTIVITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAXOIDS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34250678597     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.038513     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin. 2006;56:106-130.
2. Geddes DM. The natural history of lung cancer: a review based on rates of tumour growth. Br J Dis Chest. 1979;73:1-17.
3. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172:523-529.
4. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123(1 suppl):226S-243S.
5. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995;71:366-370.
6. Smith IE, O'Brien MER, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001;19:1336-1343.
7. Shankar LK, Sullivan DC. Functional imaging in lung cancer. J Clin Oncol. 2005;23:3203-3211.
8. Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med. 2006;47:451-469.
9. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg. 2004;77:254-259.
10. Cerfolio RJ, Bryant AS, Winikur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1903-1909.
11. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405-422.
12. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
13. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604-4610.
14. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445-7453.
15. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676-1688.
16. 18F-FDG PET. J Nucl Med. 2005;46:1144-1150.
17. 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47:14-22.
18. Wieder HA, Brücher BLDM, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
19. Westerterp M, Omloo JMT, Sloof GW, et al. Monitoring of response to preoperative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia. 2006;22:149-160.
20. Brun E, Kjellén E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135.
21. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
23. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362-8370.
24. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Trans Nucl Sci. 2000;47:1587-1594.
25. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046-2053.
26. Hudson H, Larkin R. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601-609.
27. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF. Exact and approximate rebinning algorithms for 3D PET data. IEEE Trans Med Imaging. 1997;16:145-158.
28. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92-98.
29. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol. 1997;15:2996-3018.
30. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Sheperd FA. Platinumbased versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23:2926-2936.
31. Spiro SG, Porter JC. Lung cancer: where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002;166:1166-1196.